

## Characterization of a tosylated cholesteryl derivative

SIMONA CRISTINA RIZEA<sup>(1)</sup>, CĂTĂLINA IONESCU<sup>(1)</sup>, VÉRONIQUE BARRAGAN-MONTERO<sup>(2)</sup>, J. NEAMȚU<sup>(1)</sup>

<sup>(1)</sup> Faculty of Pharmacy, University of Medicine and Pharmacy Craiova; <sup>(2)</sup> Equipe SyGReM, Institut des Biomolécules Max Mousseron, Université Montpellier 2, France


**ABSTRACT:** Purpose. This study presents the synthesis of 11-cholesteryloxy-3,6,9-trioxaundecyl-1-p-toluenesulfonate and its detailed structural characterization. Bearing a p-toluenesulfonyl group, it is a very versatile compound that can be used in the synthesis of a wide variety of derivatives that can be incorporated in liposomes, with various applications in modern drug delivery systems. Material/Methods. The compound has been prepared in a sequence of three reactions, using cholesterol as starting compound. After purification, the tosylated product has been analysed by <sup>1</sup>H, <sup>13</sup>C NMR and mass spectrometry. Results. The performed analysis confirmed the structure of the desired derivative. Conclusions. 11-cholesteryloxy-3,6,9-trioxaundecyl-1-p-toluenesulfonate has been successfully obtained as a pure compound in 58.26 % overall yield starting from cholesterol.

**KEYWORDS:** liposomes, ligands, cholesterol, NMR analysis, mass spectrometry

### Introduction

Liposomes are spherical artificial vesicles formed by one or more lipid double-layers that entrap an equal number of water compartments in their interior. Liposomes were first mentioned in 1964 by A. Bangman and R. Horne [1] and were initially studied as artificial mimics of cellular membranes. Since then, they received an increasing amount of attention from scientists, being nowadays adapted for cosmetic formulations and as drug transporting systems. One of the main advantages of liposomes as drug carriers is their ability of targeting specific cell lines, tissues or organs.[2] In passive targeting, liposomes can extravasate the vascular endothelium and selectively accumulate at infection, inflammation and tumour sites through the EPR effect (« The enhanced permeability and retention effect ») [3]. Nowadays, liposomal formulations are commercially available for cancer therapy (ovarian and breast cancer, Kaposi sarcoma, using doxorubicin or daunorubicin as active principles) and fungal infections (Amphotericin B as active principle), while other formulations are in different phases of clinical trials. [4], [5] Meanwhile, active targeting has been intensively studied. It relies on specific interactions between molecules that decorate the surface of liposomes and the targeted cells. Usually, they involve antigen-antibody and ligand-receptor interactions. Liposomes must therefore be functionalized with molecules able to selectively bind to target.

One of the strategies used for decorating liposomes with specific functional groups consists in integrating compounds containing a lipophilic part in the lipid bilayer of liposomes (Figure 1). Cholesteryl residues are often preferred as anchors, because they easily integrate in the lipid layers through hydrophobic interactions. Cholesterol is an important constituent of cellular membranes, playing an important role in their stabilisation and modulating their physical and chemical properties.[6, 7] Usually, an oxygenated spacer separates the cholesteryl part from the targeting moiety. Oligoethyleneglycols are used as spacers because of their high stability in biologic environment compared for example with esters.



**Fig.1. Schematic representation of the interaction of a liposome functionalized with a targeting group and the target cell.**

Therefore, methods that can easily afford functionalized ligands with cholesteryl-oligoethylenglycol-derived structure are of great importance in nanomedicine research. In this study, we present the synthesis and detailed characterization of 11-cholesteryloxy-3,6,9-trioxaundecyl-1-p-toluenesulfonate TsO-TetEG-C (1). The compound is known [8,9] but

it is for the first time that its detailed characterization by NMR and mass spectrometry is reported.

The p-toluenesulfonate is a good leaving group that can be displaced by a variety of nucleophiles (ions like: hydrogen sulfide, cyanide, azide, halides, alkynes, thiolates, anions of carboxylic acids, anions of active methylene compounds, neutral nucleophiles, etc.) in order to introduce different functional groups. Thus, TsO-TetEG-C is a versatile intermediate that can be used in the synthesis of ligands for liposomal preparations.

#### Material and methods

**General methods.** All reagents were Merck products and were used as received. Thin layer chromatography was carried out with pre-coated silica gel plates (E. Merck, Silica gel 60 F254) and the spots were detected by immersing the plates in 10% phosphomolybdic acid solution in ethanol followed by heating. Column chromatography was performed on silica gel 60 Å (Carlo Ebra, 35-70 µm). The NMR spectra were recorded in CDCl<sub>3</sub> at 20°C on a Bruker DRX-400 spectrometer working at 400.13 MHz for <sup>1</sup>H and 100.62 MHz for <sup>13</sup>C. The chemical shifts (δ) of <sup>1</sup>H and <sup>13</sup>C spectra are reported in ppm. The coupling constants (*J*) are reported in Hz. NMR spectra were recorded with the standard BRUKER sequences. The numbering system used in the assignments of the NMR spectra is presented in scheme 1. Mass spectra were registered on a Waters Q/ToF mass spectrometer in methanol.

#### Experimental.


Cholesteryl-p-toluenesulfonate (3) and 11-cholesteryloxy-3,6,9-trioxaundecan-1-ol (4) have been prepared using known procedures [9, 10, 11, 12]. The synthesis of 11-cholesteryloxy-3,6,9-trioxaundecyl-1-p-toluenesulfonate (1) has been realized using Bhattacharya's modified procedure of tosylation, as described below.

11-cholesteryloxy-3,6,9-trioxaundecyl-1-p-toluenesulfonate (1). p-toluenesulfonyl chloride (3.01 g, 15.47 mmol) was added to a solution of 4 (3.96 g, 7.03 mmol) in a mixture of CH<sub>2</sub>Cl<sub>2</sub> (55 mL) and pyridine (8 mL). The solution was stirred at room temperature overnight and then the mixture was partitioned between CH<sub>2</sub>Cl<sub>2</sub> and HCl 1N. The aqueous phase was washed with CH<sub>2</sub>Cl<sub>2</sub> and the reunited organic phases were washed with NaHCO<sub>3</sub>, brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate 7.5/2.5) to obtain 1 as

colorless oil (90.86 %); Rf: 0.60 (petroleum ether/ethyl acetate 1/9). For <sup>1</sup>H and <sup>13</sup>C NMR and mass spectrometry analysis, see the results and discussion part.

#### Results and discussions

11-cholesteryloxy-3,6,9-trioxaundecyl-1-p-toluenesulfonate (1) has been prepared in three steps starting from cholesterol (2) (Fig.2.).



**Fig.2. Synthesis of pTsO-TetEG-C (1). Reagents, conditions and yields: (i) tosyl chloride, pyridine, 12h at r. t., (ii) tetraethyleneglycol, dioxane, 2h at refluxing temperature; Yield: 64.13% over the two steps (i) and (ii); (iii) tosyl chloride, pyridine, CH<sub>2</sub>Cl<sub>2</sub>, 12h at room temperature, Yield: 90.86 %; Overall yield: 58.26%.**


A known protocol of tosylation using David's procedure followed by reaction of the obtained p-toluenesulfonate ester with tetraethyleneglycol in dioxane have been applied in order to obtain 11-cholesteryloxy-3,6,9-trioxaundecan-1-ol (4). The two steps have been realized without purification of the intermediate cholesteryl p-toluenesulfonate (3), leading to 11-cholesteryloxy-3,6,9-trioxaundecan-1-ol (4) in 64% yield over the two steps. Subsequent activation of the hydroxyle group of 4 as p-toluenesulfonyl ester afforded the pure desired compound 1 in 90.86% yield.

<sup>1</sup>H and <sup>13</sup>C NMR spectra of pure TsO-TetEG-C have been recorded. The <sup>1</sup>H NMR spectrum (Fig. 3) contains the following signals:

the peaks characteristic for the cholesteryl group: the singlets of H<sub>18</sub> and H<sub>19</sub>; three doublets corresponding to H<sub>21</sub>, H<sub>26</sub> and H<sub>27</sub>; a massif of peaks due to the four cholesteryl rings and two multiplets associated to H<sub>3</sub> and H<sub>6</sub>, the most deshielded proton of the cholesterol residue.

the peaks of the tetraethyleneglycol-derived spacer. H<sub>28</sub>-H<sub>33</sub> gives as signal a massif of peaks integrating for 12 protons (3.56-3.65 ppm), while H<sub>34</sub> and H<sub>35</sub>, being in the proximity of the p-toluenesulfonyl ester, are more deshielded, at 3.48 and 4.16, respectively.

the peaks of the p-toluenesulfonyl group: H<sub>2</sub>, H<sub>3</sub>, H<sub>5</sub> and H<sub>6</sub> give signals specific for para-substituted aromatic rings while the methyl group gives a singlet integrating for three protons at 2.44 ppm.



**Fig.3.** Full <sup>1</sup>H NMR spectrum of pTsO-TetEG-C (spectrum A) and details of the regions: 7.2-7.9 ppm (detail 1); 3.5-4.2 ppm (detail 2); 2.3-2.5 ppm (detail 3). The peaks of the p-toluenesulfonyl group are indicated in blue windows; the peaks of tetraethyleneglycol residue are marked in a green window; the remaining peaks belong to cholesterol.

The <sup>1</sup>H NMR data of pTsO-TetEG-C are gathered in Table 1.

**Table 1:** <sup>1</sup>H NMR chemical shifts and coupling constants of pTsO-TetEG-C

Hydrogen atom	δ (ppm), multiplicity and coupling constants	Hydrogen atom	δ (ppm), multiplicity and coupling constants
H <sub>1</sub> ,H <sub>2</sub> ,H <sub>4</sub> , H <sub>7</sub> ,H <sub>8</sub> ,H <sub>9</sub> , H <sub>11</sub> ,H <sub>12</sub> , H <sub>14</sub> ,H <sub>15</sub> , H <sub>16</sub> ,H <sub>17</sub> ,H <sub>20</sub> , H <sub>22</sub> ,H <sub>23</sub> ,H <sub>24</sub> ,H <sub>25</sub>	0.83-2.39 (m, 28H)	H <sub>27</sub>	0.86 (d, 3H, <sup>3</sup> J <sub>H27-H25</sub> =6.6 Hz)
H <sub>3</sub>	3.13-3.20 (m, 1H)	H <sub>28</sub> -H <sub>33</sub>	3.56-3.65 (m, 12H)
H <sub>6</sub>	5.32-5.34 (m, 1H)	H <sub>34</sub>	3.68 (m, 2H)
H <sub>18</sub>	0.67 (s, 3H)	H <sub>35</sub>	4.16 (m, 2H)


H <sub>19</sub>	0.99 (s, 3H)	H <sub>3</sub> , H <sub>5</sub>	and <sup>3</sup> J <sub>H3'-H2'</sub> =8.0 Hz)
H <sub>21</sub>	0.90 (d, 3H, <sup>3</sup> J <sub>H21-H20</sub> =6.5 Hz)	H <sub>2</sub> , H <sub>6</sub>	and <sup>3</sup> J <sub>H2'-H3'</sub> =8.3 Hz)
H <sub>26</sub>	0.85 (d, 3H, <sup>3</sup> J <sub>H26-H25</sub> =6.6 Hz)	H <sub>7</sub>	2.44 (s, 3H, H <sub>7</sub> )

For the <sup>13</sup>C NMR analysis, <sup>13</sup>C APT experiment has been recorded. In this experiment, -CH and -CH<sub>3</sub> atoms have positive phases, while -CH<sub>2</sub> and carbons with no attached protons have negative phases (Figure 3). The spectrum contains:

The peaks of cholesterol, in good agreement with literature data [13,14];

The peaks of the secondary carbon atoms belonging to the tetraethyleneglycol-derived spacer, having negative phases;

The peaks of the p-toluenesulfonyl group: C7' (primary C atom, with positive phase); C2', C3', C5', C6' (CH, with positive phases); C1' and C4' (quaternary atoms with negative phases).



**Fig.4.** <sup>13</sup>C APT spectrum of pTsO-TetEG-C. The peaks of the p-toluenesulfonyl group are indicated in blue windows; the peaks of tetraethyleneglycol residue are marked in a green window; the remaining peaks belong to cholesterol.

The <sup>13</sup>C NMR data of pTsO-TetEG-C are presented in Table 2.

**Table 2:** <sup>13</sup>C NMR chemical shifts of pTsO-TetEG-C

Carbon atom	δ (ppm)	Carbon atom	δ (ppm)
C <sub>1</sub>	37.1	C <sub>19</sub>	19.2
C <sub>2</sub> , C <sub>16</sub>	28.1 and 28.2	C <sub>20</sub>	35.6
C <sub>3</sub>	79.3	C <sub>21</sub>	18.7
C <sub>4</sub>	38.9	C <sub>22</sub>	36.0
C <sub>5</sub>	140.6	C <sub>23</sub>	23.7
C <sub>6</sub>	121.4	C <sub>24</sub>	39.4
C <sub>7</sub>	31.8	C <sub>25</sub>	27.8
C <sub>8</sub>	31.7	C <sub>26</sub> , C <sub>27</sub>	22.4 and 22.7
C <sub>9</sub>	50.0	C <sub>28</sub> -C <sub>33</sub>	67.1, 70.4 (2C)

			70.5, 70.6, 70.7
C <sub>10</sub>	36.7	C <sub>34</sub>	68.5
C <sub>11</sub>	20.9	C <sub>35</sub>	69.7
C <sub>12</sub>	39.6	C <sub>1'</sub>	144.6
C <sub>13</sub>	42.2	C <sub>2'</sub> ; C <sub>6'</sub>	129.7
C <sub>14</sub>	56.6	C <sub>3'</sub> ; C <sub>5'</sub>	128.7
C <sub>15</sub>	24.1	C <sub>4'</sub>	132.9
C <sub>17</sub>	56.0	C <sub>7'</sub>	21.5
C <sub>18</sub>	11.8		

Bidimensional spectra of homonuclear (<sup>1</sup>H-<sup>1</sup>H) and heteronuclear (<sup>1</sup>H-<sup>13</sup>C) correlations have also been recorded. They confirmed the assignments presented above and provided accurate attribution of peaks in the <sup>13</sup>C spectrum.

The structure of TsO-TetEG-C has also been proved by mass spectrometry (Figure 6). TsO-TetEG-C ionises in positive mode using electrospray ionization at m/z=739.78 [M+Na]<sup>+</sup>.




Fig.5. Mass spectra of pTsO-TetEG-C in methanol in negative mode (spectrum A) and positive mode (spectrum B).

## Conclusion

In this study, we have presented the preparation of 11-cholesteryloxy-3,6,9-trioxaundecyl-1-p-toluenesulfonate with an overall yield of 58.26 % (calculated starting from cholesterol). A detailed presentation of the <sup>1</sup>H and <sup>13</sup>C NMR spectra of the compound has been realized and the mass spectra of the compound have been presented. Being a tosylate and having a cholesterol-derived structure, the product can be used in the synthesis of various compounds with applications in liposomal preparations.

## Acknowledgements

This work was supported by the POSDRU/88/1.5/S/52826 programme.

## References

- Bangham A, Horne R. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope, *J Mol Biol* 1964; 8: 660-68.
- Yokoyama M. Drug targeting with nano-sized carrier systems, *J Artif Organs* 2005; 8: 77-84.
- Maeda H, Wu J, Sawa T et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, *J. Contr. Release* 2000; 65: 271-84.
- Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery, *J. Contr. Release* 2010; 148: 135-46.
- Sharma A, Sharma U. Liposomes in drug delivery: progress and limitations, *International Journal of Pharmaceutics* 1997; 154: 123-40.
- Papahadjopoulos D, Cowden M, Kimelberg H. Role of cholesterol in membranes. Effects on phospholipid-protein interactions, membrane permeability, and enzymic activity, *Biochim. Biophys. Acta* 1973; 330: 8-26.
- Ohvo-Rekila H, Ramstedt, B, Leppimäki P et al. Cholesterol interactions with phospholipids in membranes, *Progr. Lipid Res* 2002; 41: 66-97.
- Bhattacharya S, Krishnan-Ghosh Y. Membrane formation from oxyethylene bearing cationic cholesterol derivatives, *Indian J Chem B Org* 2001; 40B: 891-94.
- Bhattacharya S, Krishnan-Ghosh Y. Vesicle Formation from Oligo(oxyethylene)-Bearing Cholesteryl Amphiphiles: Site-Selective Effects of Oxyethylene Units on the Membrane Order and Thickness, *Langmuir* 2001; 17: 2067-75.

10. Davis M. Chemotherapy of schistosomiasis. V. Cholesteryl and cholyl derivatives of 4-amino-2-methoxyphenyl ethers, *J Chem Soc* 1962: 178-191.
11. Hai L, Fan J, Zhang Z et al. Synthesis of Cholesterylated Thiogalactosides for Gene Delivery, *Synth Commun* 2006; 36: 2633-48.
12. Barragan-Montero V, Winum J-Y, Moles J-P et al. Synthesis and properties of isocannabinoid and cholesterol derivatized rhamnosurfactants: application to liposomal targeting of keratinocytes and skin, *Eur J Med Chem* 2005; 40: 1022-1029.
13. Smith W. NMR vs. molecular modelling Part II—Steroid chemical shift calculations, *Magn. Reson. Chem.* 1999; 37: 103-06.
14. Ionescu C, Fruchier A, Chelarescu M et al. Characterization of two cholesterol derivatives, *Annals of the University of Craiova, The Chemistry Series* 2011; XL (1): 41-46.

---

*Correspondence Adress: Simona Cristina Rizea, PhD Student, Faculty of Pharmacy, University of Medicine and Pharmacy Craiova, Str. Petru Rareș nr. 2-4 Craiova 200349, Dolj, România, e-mail: mondeasimona@yahoo.com*